AI and ML solutions are empowering Clario scientists to analyze clinical trial participant data collection more efficiently, accurately and quickly. These new tools optimize operations, integrate platforms, enhance patient privacy, and improve data quality while reducing errors.
- Since 2018, Clario has implemented over 30 AI solutions, more than half of which are directly integrated into the Clario platform through in-house development and AI-driven strategic partnerships.
- AI and ML support empowers Clario scientists to improve the quality of data collection, reduce the potential for error, and provide faster data analysis without compromising accuracy.
- Over 70 clinical trials are enrolled in various Clario AI models across the platform.
Philadelphia, May 23, 2023 /PRNewswire/ — Clario, a healthcare research technology company that provides leading endpoint technology solutions for clinical trials, today announced a major milestone in the integration of artificial intelligence (AI) and machine learning (ML) into clinical trial data collection. I’ve made it clear that progress has been made. Through proprietary development and strategic partnerships. Over 30 solutions have been applied, more than half of which are already active on various Clario platforms. These integrations represent a significant evolution in how the company conducts clinical trial endpoint analysis. By combining AI tools with deep scientific expertise, Clario achieves faster and more accurate results than ever before. In addition, the integration has enhanced operational efficiency and patient privacy protection.
“When it comes to AI technology and clinical trials, no single solution matters,” he said. Todd RudeChief Medical Officer, Clario. “Clinical trials are complex and specific to the drug under study, requiring a tailor-made solution. That’s why we develop AI solutions that address specific challenges across the human body.Today, our various AI models are enrolled in over 70 clinical trials, and our clients and their patients are already We are seeing the benefits of an enhanced ability to collect digital data and then analyze it more quickly and accurately.”
“AI is transforming clinical trials, but we need to think carefully about how we develop AI for such a complex field. to identify meaningful applications of artificial intelligence and improve the performance of data collection and analysis.” It is an effective tool to assist users in their daily work. AI in clinical trials is clearly out of its infancy and we are excited to be at the forefront of progress. In this ever-evolving landscape,” he said. Achim Schülke, EVP, Chief Innovation Officer, Clario.
Since 2018, Clario has applied more than 30 AI solutions to optimize operations, integrate platforms, enhance patient privacy, and improve the quality and accuracy of scientists’ data end-of-life while reducing errors. Enhanced point analysis. AI solutions across Clario’s technology platform include:
- Cardiac safety: To improve data quality and reduce the risk of data loss, an AI-supported quality assessment of continuous 12-lead ECG recording is under development. This allows you to quickly identify poor quality records and quickly address issues directly in the field. level.
- eCOAs: To improve patient safety and data quality, eCOA Science risk monitoring and analytics solutions identify potential issues early throughout clinical trials and enable corrective action. Additionally, consistency checks across multiple eCOA instruments are being conducted to ensure more robust scientific data and improve researcher supervision and experience.
- imaging: Receiving, processing, quality control and analysis with the help of AI tools such as automatic labeling to automatically identify up to 10,000 images (MRI, X-ray, etc.) per week, and facial masking to enhance patient privacy is faster than ever, reducing manual quality control time per video from 1 hour to 1 minute, and enabling automatic motion detection for quality metrics. Clario also uses a powerful AI framework for image classification, segmentation, landmark detection, and regions of interest.
- Respiratory: AI algorithms can now automatically analyze spirometry loops to detect technical errors to support immediate quality control and ensure consistent and objective data collection across clinical and trial environments It is now possible. Potentially problematic loops can be flagged for further review by trained experts and used to further enhance the algorithms to support future research.
Clario’s innovation, development and implementation of multiple AI solutions for data endpoint analytics are transforming the efficiency, accuracy and speed of clinical trials. For more information about Clario and its artificial intelligence solutions, visit Clario.com.
About Clario
Clario is a leading healthcare research and technology company that produces the industry’s richest set of clinical evidence for pharmaceutical, biotech and medical device partners. Across distributed, hybrid and site-based trials, our deep scientific expertise, global scale and industry’s broadest endpoint technology platform enable our partners to transform lives. Clario has the only technology platform that combines eCOA, cardiac safety, medical imaging, precision motion and respiratory endpoints. Clario’s global team of scientific, technical and operational experts has helped conduct over 27,000 clinical trials and over 500 FDA and EMEA approvals in more than 100 countries, involving more than 7 million patients contributed to new drug approvals. Our innovations have transformed clinical trials in his 50 years.
For more information, visit Clario.com or follow us on LinkedIn. twitter.
Clario Media Contact
Duncan Cantor
[email protected]
Source: Clario
